Best Read Articles on COVID-19 Drug-Related News in 2021
The attention-getting articles about COVID-19 included news about Pfizer's booster and the FDA's rejection Zyesami (aviptadil) for treatment of COVID-19-related respiratory failure.
FDA Rejects EUA for COVID-19 Respiratory Failure Therapy
The FDA didn’t have enough data to assess the risks and benefits of Zyesami.
Amber Specialty, Hy-Vee to Dispense Regeneron Monoclonal Antibody for COVID-19
Regeneron also announced an expanded contract with the U.S. government for the purchase of additional doses of REGEN-COV.
Pfizer Submits EUA for COVID-19 Vaccine Booster for All Adults
The FDA had previously issued an EUA for those over the age of 65 and those at high risk for severe COVID-19 or exposure to the virus.
Concerns About Childhood COVID-19 Vaccines Persist, Despite FDA Committee OK
Some have expressed concerns about the risk of myocarditis and unknown longer-term side effects.
FDA Issues EUA for Pfizer COVID-19 Vaccine for Children
The dose is one-third of the dose given to people 12 years and older.
Iowa Expands PBM Legislation to Address Concerns of Independent Pharmacies
May 16th 2025A new law in Iowa, if signed by the governor, will mandate 100% pass-through of rebates, increased financial transparency, and a minimal payment for pharmacies. Critics say it will be the most costly mandate in the state’s history.
Read More
Is Arkansas’ New PBM Law the Right Path Forward for Reform? No One Knows Yet
May 9th 2025It could improve access to community pharmacies and lower prices. Or it will limit access to critical drugs and impact payers’ ability to contract for a broad range of services. Industry leaders are unsure about the impact of Arkansas’ law banning PBMs from owning pharmacies.
Read More
